Finen 20mg Tablet 10pcs

Composition

FINERENONE

Uses of Finen 20mg Tablet

Finerenone is used to prevent chronic kidney disease.

Side Effects of Finen 20mg Tablet

• High potassium level (hyperkalemia)
• Weakness or tiredness
• Feeling sick (nausea)
• Numbness in the hands and lips
• Muscle cramps
• Decreased pulse rate
• Low sodium level (hyponatremia)
• Tiredness
• Headache
• Confusion
• Muscle weakness, spasms or cramps
• Decrease in how well the kidneys filter blood (glomerular filtration rate decreased)
• High uric acid level (hyperuricaemia)

Quick Suggestions:

• A healthy, balanced diet lowers your risk of kidney disease. Keep your blood pressure and cholesterol at a healthy level.
• A well-balanced diet should include plenty of fruits and vegetables.
• Include starchy foods such as potatoes, wholegrain bread, rice, or pasta in your main meal.
• For a protein source, include beans or pulses, fish, eggs, or meat in your daily diet.
• Limit intake of saturated fat, salt, and sugar.
• Limit the amount of potassium or phosphate in your diet.
• Quit smoking. Avoid or limit the consumption of alcohol.
• Do not skip any laboratory appointments, as your doctor will need to regularly check your liver and kidneys and blood and urine samples.

Indications:

Management of chronic kidney disease (stages 3 and 4 with abnormal presence of albumin in the urine) associated with type 2 diabetes in adults

Pharmacology

Mechanism of Action:

• Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR).
• It blocks MR-mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels) tissues, which can contribute to fibrosis and inflammation.
• Finerenone has high potency and selectivity for MR, with no significant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.

Pharmacokinetics:

• Absorption: Finerenone is completely absorbed after oral administration, with an absolute bioavailability of 44%. Peak plasma concentration (Cmax) is achieved within 0.5 to 1.25 hours after dosing.
• Distribution: Volume of distribution (Vss) is 52.6 L. Plasma protein binding is 92%, mainly to serum albumin.
• Elimination: Terminal half-life is 2 to 3 hours. Systemic blood clearance is about 25 L/h.
• Metabolism: Primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites. About 80% of the dose is excreted in urine.

Dosage & Administration of Finen 20mg Tablet

• Starting Dose:
  • eGFR ≥60 mL/min/1.73 m²: 20 mg once daily
  • eGFR ≥25 to <60 mL/min/1.73 m²: 10 mg once daily
  • eGFR <25 mL/min/1.73 m²: Not recommended
• Dose Adjustment: Increase dosage to 20 mg once daily after 4 weeks based on eGFR and serum potassium levels.
• Pediatric Use: Safety and efficacy not established for those under 18.
• Geriatric Use: No dose adjustment is required based on study data.
• Hepatic Impairment: Avoid severe hepatic impairment. No adjustment is needed for mild/moderate impairment but monitor potassium levels.

Missed Dose: 

Take as soon as possible on the same day. If missed for a day, skip and resume the next dose as scheduled.

Overdose:

• Symptoms: Likely hyperkalemia.
• Treatment: Discontinue Finerenone. Standard treatment for hyperkalemia. Finerenone is not efficiently removed by hemodialysis.
• Administration: Tablets can be taken with or without food. If swallowing is difficult, tablets can be crushed and mixed with water or soft foods.

Interaction

• Strong CYP3A4 Inhibitors: Contraindicated (e.g., itraconazole, ketoconazole, ritonavir).
• Moderate/Weak CYP3A4 Inhibitors: Monitor serum potassium and adjust the dose as needed.
• Strong/Moderate CYP3A4 Inducers: Avoid use (e.g., rifampicin).
• Drug-Food Interactions: Avoid grapefruit or grapefruit juice.

Contraindications

• Strong CYP3A4 inhibitors
• Adrenal insufficiency

Pregnancy & Lactation

• Pregnancy: No data on risks. Animal studies show developmental toxicity. Avoid unless necessary.
• Lactation: Likely present in breast milk. Avoid breastfeeding during and 1 day after treatment.

Precautions & Warnings

• Monitor serum potassium and eGFR before and during treatment.
• Do not start treatment if serum potassium >5.0 mEq/L.

Storage:

Store below 30°C, away from light and moisture. Keep out of reach of children.